***The Iowa Standard is an independent media voice. We rely on the financial support of our readers to exist. Please consider a one-time sign of support or becoming a monthly supporter at $5, $10/month - whatever you think we're worth! If you’ve ever used the phrase “Fake News” — now YOU can actually DO something about it! You can also support us on PayPal at [email protected] or Venmo at Iowa-Standard-2018 or through the mail at: PO Box 112 Sioux Center, IA 51250

On Wednesday, U.S. Senator Josh Hawley (R-Mo.) unveiled two new bills in his Patients First Agenda to Cut Drug Costs. In addition to Senator Hawley’s already-introduced Cap Insulin Prices Act, the agenda includes the Fair Prescription Drug Prices for Americans Act and the Ending the Prescription Drug Kickback Act of 2023.

If enacted, his three-part agenda will together target the biggest abuses in the prescription drug market to reduce costs for patients.

“Our prescription drug market is rigged in favor of Big Pharma and Big Insurance and patients are paying the price. Americans foot the bill for the most costly prescription drug prices in the world—all while middlemen negotiate backroom deals to extract financial kickbacks that drive prices further up and prevent lower-cost alternatives,” said Senator Hawley. “These conditions inflate prices, strain the budgets of American families, and create unacceptable barriers to care. It’s time to stop subsidizing lower drug costs for foreigners, end Big Insurance’s pay-to-play scheme, and put American patients first.”

The Fair Prescription Drug Prices for Americans Act would:

  • Prohibit pharmaceutical companies from selling a drug in the United States at a higher price than the average price of the drug sold in the other G-7 advanced economies.
  • Impose stiff civil monetary fines for Big Pharma if they sell a drug at a higher list price in the United States than the average price of the drug sold in Canada, France, Germany, Japan, Italy, and the United Kingdom.

View the full bill text here.

The Ending the Prescription Drug Kickback Act of 2023 would:

  • Entirely prohibit, without exception, prescription drug rebates in both federal health programs like Medicare and private insurance plans, including those intended to influence formulary tier placement or its equivalent.
  • Restore transparency and fairness to the prescription drug market and put patients on a more level playing field with large corporations.

View the full bill text here.

Author: Press Release


Please enter your comment!
Please enter your name here